Giuseppe Pettinato, Ph.D.
Instructor in Medicine
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Division of Gastro.
330 Brookline Ave
Boston MA 02215
|University of Catania, Catania||Ph.D.||2008||Andrological Science and Human Reproduction|
|University of Catania, Catania||MS||2002||Molecular Biology|
|University of Catania, Catania||BS||2000||Biology|
|Medical University of South Carolina/Clemson University, South Carolina||Postdoctoral Fellow||2012||Bioengineering of materials|
|Virginia Commonwealth University, Virginia||Research Associate||2015||Medical Bioengineering|
1995 - 2000
2002 - 2007
Research Award for Ph.D. Studies
Young Investigator Award
Co-chair State-of-the-Art Workshop: Organ Engineering & Repair
2016 nominee for the ADA Pathway to Stop Diabetes Awards
Chair the CTRMS Workshop III & Oral session: iPS Derived Cells & Stem
TTS-CTRMS Scientific Award
CTRMS Scientific Congress Award
2021 - 2022
Visiting Professor at Department of Drug and Health Sciences (DSFS)
As a biologist and embryologist who has received his training in bioengineering, my major research focus is to study the fundamental basis underlying cell biology, with a particular interest in the differentiation of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) by following the in vivo developmental cues that drive these cells to become liver and pancreatic organoids. These organoids can be used as a drug screening model in vitro, or in regenerative medicine to treat liver and pancreatic degenerative diseases through cell transplantation therapy. My current research focuses on the development of HLA-Knockout hiPSCs liver and pancreatic organoids.
A recent new endeavor in my research is the generation of free-floating human intestinal and colonic organoids to be used as Inflammatory Bowel Disease in vitro models. These new organoids hold great promise of being able to predict fibrotic events in Crohn's disease patients even before the development of clinical evidence. This will potentially allow for future screenings of patients' own factors to determine their risks of developing intestinal strictures in the presence of IBD.
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
2023 L.I.F.E.R. Award
Jul 1, 2023 - Jun 30, 2025
Liver Institute and Foundation for Education and Research
Multicellular Organoids to study HBV infectious models and targeted antiviral drugs.
Role Description: Multicellular liver organoids derived from hiPSCs with supportive cells will be used to study HBV infectious models and test antiviral drugs. The goal of this grant is to develop an in vitro model for HBV using human multicellular liver organoids that present all the features of liver tissue.
Role of Alpha-1 Antitrypsin in hepatocyte-clusters and hepatocyte-like clusters in the ex vivo survival.
Role Description: The goal of this study is the formation of hepatospheres from HPH and hiPSCs and further evaluation of their functions in vitro and in vivo. We will also evaluate the effect of A1AT on ex-vivo survival and the function of HPH in the hepatospheres both in vitro and in vivo.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.